Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Inclusion Criteria:

• >18 years old
• histologically confirmed solid tumor malignancy
• refractory to available therapy or for which no therapy is available
• adequate organ function

Exclusion Criteria:

• CNS malignancy
• significant GI disease
• at risk for prolonged QT interval